Form 4: Aprea Therapeutics CEO Boosts Stake with New Equity Awards

Aprea Therapeutics' President and CEO, Oren Gilad, acquired 20,175 restricted stock units and 80,700 stock options, increasing his beneficial ownership in the company.

Summary

• Oren Gilad, President/CEO and Director of Aprea Therapeutics, Inc. (APRE), acquired 20,175 shares of common stock in the form of Restricted Stock Units (RSUs).
• These RSUs were acquired at a price of $0.00 and will vest in three equal annual installments starting March 12, 2027, contingent on continued employment.
• Gilad also acquired 80,700 stock options with an exercise price of $0.765 per share.
• Twenty-five percent of these options vest on March 12, 2027, with the remainder vesting ratably over the subsequent 36 months, also subject to continued employment.
• Following these transactions, Gilad directly beneficially owns 393,895 shares of common stock and 80,700 stock options.
• He indirectly beneficially owns 1,200 shares through his daughter and 600 shares through his son, though he disclaims beneficial ownership of these.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as increased insider ownership through equity awards generally signals management's confidence and long-term commitment to the company's success.

Positives

• Increased insider ownership by the President/CEO and Director, Oren Gilad, through the acquisition of 20,175 Restricted Stock Units and 80,700 stock options.
• The equity awards align management's interests with those of shareholders, as vesting is tied to continued employment and future performance.

Negatives

• No explicit negatives are present in this Form 4 filing, which primarily reports insider transactions.

Risks

• The vesting of both Restricted Stock Units and stock options is contingent upon the reporting person's continued employment through the applicable vesting dates, introducing a retention risk.

Future Outlook

The vesting schedules for both the Restricted Stock Units and stock options extend into future years (starting March 12, 2027, and continuing over 36 months for options), indicating a long-term incentive structure tied to the reporting person's continued employment and the company's future performance.

Management Comments

• These shares represent restricted stock units and shall vest and be settled in the Issuer's common stock in three (3) equal annual installments beginning on March 12, 2027, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
• The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
• Twenty-five percent of these options vest on March 12, 2027, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.

Industry Context

StockSavvy.ai notes that equity awards to top executives like Oren Gilad are a standard practice in the biotechnology and pharmaceutical industries, aiming to incentivize long-term commitment and align executive interests with shareholder value creation. This type of compensation is particularly common in companies like Aprea Therapeutics, which often have long development cycles and rely on key personnel for strategic execution.

Comparison to Industry Standards

• The grant of RSUs and stock options to a CEO is a common compensation practice across industries, particularly in growth-oriented sectors like biotech.
• The vesting schedule, with a one-year cliff for options and multi-year ratable vesting, is typical for executive equity awards, similar to practices seen at companies like Moderna or BioNTech, which use long-term incentives to retain talent.
• The exercise price of $0.765 for the options suggests they were granted at or near the market price on the grant date, a standard practice for incentive stock options.

Stakeholder Impact

• Shareholders: Potentially positive, as increased insider ownership aligns management's interests with shareholder value creation.
• Employees: No direct impact on general employees, but it reinforces the company's executive compensation structure.

Next Steps

• Continued employment of Oren Gilad through vesting dates for RSUs and stock options.
• Future vesting events for RSUs starting March 12, 2027, in three equal annual installments.
• Future vesting events for stock options starting March 12, 2027 (25%), with remaining options vesting ratably over 36 months.

Key Dates

Recommendation

While the increased insider ownership through equity awards is a positive signal of management's commitment, this Form 4 filing primarily details compensation. It does not provide new operational or financial performance data that would warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and await further operational updates or financial results to assess the company's fundamental performance.

Keywords

Aprea Therapeutics, APRE, Oren Gilad, Insider Trading, Form 4, Restricted Stock Units, Stock Options, Equity Awards, CEO, Director, Beneficial Ownership